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Abstract: Despite significant progress, new therapeutic approaches for advanced non-small 
cell lung cancer (NSCLC) are highly needed, particularly for the treatment of patients with 
squamous cell carcinoma. The epidermal growth factor receptor (EGFR) is often overex-
pressed in NSCLC and represents a relevant target for specific treatments. Although EGFR 
mutations are more frequent in non-squamous histology, the receptor itself is more often 
overexpressed in squamous NSCLC. Necitumumab is a human monoclonal antibody that 
is able to inhibit the EGFR pathway and cause antibody-dependent cell cytotoxicity. This 
drug has been studied in combination with first-line chemotherapy for advanced NSCLC 
in two Phase III trials, and a significant survival benefit was reported in squamous NSCLC 
(SQUIRE trial); by contrast, necitumumab did not prove itself beneficial in non-squamous 
histotype (INSPIRE trial). On the basis of the SQUIRE results, necitumumab was approved 
in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous 
NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-
expressing tumors. The aim of this review is to describe the tolerability and the efficacy of 
necitumumab by searching the available published data and define its potential role in the 
current landscape of NSCLC treatment.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for a significant proportion of the 
global cancer-related deaths in spite of continuous therapeutic improvements. Most 
patients are diagnosed with advanced disease and, because curative treatments are 
not available at this stage, the only available option is palliative systemic therapy, 
which aims at prolonging survival and improving symptoms.1 Different histologic 
subtypes of NSCLC can be identified, the most representative being adenocarci-
noma (ADC) and squamous cell carcinoma (SCC). Currently, therapeutic options 
for SCC are more limited compared to ADC, as the latter subtype can be treated 
with “new” agents like pemetrexed and bevacizumab, as well as specific targeted 
therapies when sensitizing mutations of the epidermal growth factor receptor 
(EGFR) gene or rearrangements involving the anaplastic lymphoma kinase (ALK) 
gene are identified.2
Notably, although activating mutations of the EGFR gene are more typical of 
non-squamous histology, the EGFR protein itself is often highly expressed in both 
histologic subtypes, and it has been reported that its over-expression in SCC is even 
more pronounced than in ADC (82% vs 44%);3 hence, it has been postulated that 
EGFR could represent an eligible target for both histotypes. Cetuximab, a chimeric 
murine/human monoclonal antibody (mAB) targeting EGFR, currently registered for 
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the treatment of colorectal and head and neck cancers, was 
studied in combination with first-line chemotherapy in an 
open-label, Phase III trial involving patients with advanced 
NSCLC who were not selected for histology (FLEX trial), 
achieving a significant advantage in terms of overall survival 
(OS) compared to chemotherapy alone (11.3 vs 10.1 months; 
hazard ratio [HR]=0.871; P=0.044);4 a retrospective analysis 
suggested that the OS advantage achieved with the addition of 
cetuximab to chemotherapy was limited to patients with high 
expression of EGFR, while this benefit was not confirmed in 
patients with low expression of the protein.5
Necitumumab (IMC-11F8, LY3012211) is a second-
generation human mAB directed against the extracellular 
region of EGFR, developed by Eli Lilly & Co (Indianapolis, 
IN, USA); other agents in the same drug class include cetux-
imab and panitumumab, which are available for clinical use 
in other solid malignancies.6
Recently, significant data regarding activity, efficacy, and 
tolerability of necitumumab in NSCLC have been collected 
and the aim of this review is to define the potential role of 
this drug in the treatment of NSCLC by exploring the avail-
able literature; for this purpose, relevant articles indexed in 




Under normal conditions, when EGFR interacts with its 
ligand, the epidermal growth factor, the former undergoes 
dimerization and subsequent phosphorylation, leading 
to the activation of downstream signaling pathways that 
involve a number of subsequent protein-based cascades, 
such as the Kirsten rat sarcoma/rapidly accelerated 
fibrosarcoma/mitogen-activated protein kinase pathway 
and the phosphatidylinositol-3-kinase/protein kinase B 
pathway; these signaling cascades ultimately lead to the 
promotion of cell proliferation and survival. While this 
process has a physiologic role in the development of tissues 
and organs, it is also a key player in the growth of several 
types of neoplasms, including lung cancer.7 Necitumumab 
contains an antigen-binding fragment, known as FAB-11F8, 
with high affinity for one of the ligand-binding extracel-
lular domains of EGFR;8 as a consequence of competitive 
binding, the mAB prevents the dimerization of EGFR and 
the subsequent signaling cascade, resulting in internaliza-
tion and degradation of the receptor, ultimately followed 
by inhibition of proliferation and survival.9 Additionally, 
since necitumumab belongs to the immunoglobulin (Ig) G1 
class, it retains the ability to induce antibody-dependent cell 
cytotoxicity (ADCC) by stimulating response from adaptive 
immune cells (such as lymphocytes), which exert their activ-
ity on opsonized neoplastic cells (eg, activating the perforin/
granzymes mechanism), resulting in immune-mediated cell 
lysis.10,11 The mechanisms of action of necitumumab are 
summarized in Figure 1.
Pharmacokinetics
Necitumumab shares common pharmacokinetic features with 
other therapeutic mABs, which are unavailable by oral route 
and get distributed in tissues at slow speed and low volumes, 
resulting in increased half-life compared to non-antibody 
drugs; additionally, the elimination routes of such agents 
are only partially documented, and involve degradation to 
peptides after being internalized into their target cells, pro-
teolysis within the liver or the reticuloendothelial system, 
as well as nonspecific endocytosis. In a first-in-human, 
dose-escalation, Phase I trial, the maximum tolerated dose 
of necitumumab was identified to be 800 mg; at this dose, 
the half-life of necitumumab was ≈7 days; additionally, its 
mean clearance decreased in a less than dose-proportional 
pattern, while its maximum serum concentration and area 
under the concentration versus time curve extrapolated from 
time 0 to infinity values increased disproportionately to the 
dose of necitumumab. These nonlinear pharmacokinetics 
findings suggest a saturable clearance mechanism for this 
drug; additionally, its metabolism is not apparently related 
to height or weight, indicating fixed dose as the most suitable 
choice for necitumumab.12,13
Preclinical data
Necitumumab was able to inhibit in vitro proliferation of a 
series of tumor cell lines characterized by overexpression of 
EGFR, including epidermal, pancreatic, and colorectal cell 
lines.14 Additionally, the binding and ADCC activities of 
necitumumab were subjects of comparisons with cetuximab 
and panitumumab; in colorectal cells, necitumumab showed 
an EGFR binding activity similar to cetuximab and signifi-
cantly higher than panitumumab, although panitumumab had 
a higher affinity for the receptor;15 in NSCLC cells, necitu-
mumab and cetuximab, both belonging to the IgG1 class, 
were rapidly internalized into target cells and were able to 
induce a relevant ADCC at 1.0 nM with a magnitude directly 
proportional to EGFR expression, while panitumumab was 
internalized more slowly and, being an IgG2, was not able 
to activate ADCC.16,17 Finally, since cetuximab was associ-
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Necitumumab in non-small cell lung carcinoma
potentially related to its chimeric structure (mouse/human), 
the allergenic potentials of cetuximab, necitumumab, and 
panitumumab were evaluated, measuring the activity of 
anti-galactose-alpha-1,3-galactose IgE as a proper marker: 
notably, both necitumumab and panitumumab, which are 
fully-human mABs, induced a significantly lower IgE activity 
compared to cetuximab.18
Necitumumab confirmed its tumor inhibiting activity, 
alone or in combination with chemotherapy, also against epi-
dermoid, colorectal, and pancreatic human xenograft models 
in immunosuppressed mice.19 Notably, among several antine-
oplastic treatments employed on NSCLC xenograft models, 
including necitumumab in combination with pemetrexed, 
paclitaxel, or cisplatin–gemcitabine doublet, the latter com-
bination resulted particularly effective in terms of tumor 
shrinkage; further data suggest that part of the activity of this 
combination might be connected with the overexpression of 




The first-in-human, dose-escalation, Phase I trial involving 
necitumumab included 60 patients affected by advanced solid 
tumors, including colo-rectal, esophageal, ovarian, pancreatic, 
prostate, renal, gastric, and lung cancer, who were random-
ized to a weekly schedule (arm A; 29 patients) or to an every 
2-week schedule (arm B; 31 patients); each arm included six 
escalating cohorts of three to four patients receiving different 
doses of the drug (100–200–400–600–800–1,000 mg). Each 
patient received a single administration of necitumumab 
at the planned dose, followed by 2 weeks of “rest” from 
Figure 1 in normal conditions, the extracellular interaction between eGFR and its ligand, eGF, leads to dimerization of the receptor, binding with ATP in the intracellular 
region of the receptor, and activation of two main pathways, the first being RAS-RAF-MEK-ERK and the second being PI3K-AKT-mTORc (which is inhibited by PTEN).
Notes: Both pathways ultimately lead to proliferative and anti-apoptotic signals. in tumor cells with overexpressed or mutated eGFR, this mechanism is generally overactivated. 
Necitumumab binds the extracellular region of eGFR, preventing its interaction with eGF and the following downstream cascade. Additionally, the necitumumab–eGFR 
complex can induce ADCC by various types of immune system cells, such as T lymphocytes, NK lymphocytes, and macrophages; in the example, an activated cytotoxic 
T-cell releases ADCC effectors (the perforin/granzyme system), ultimately leading to the death of the target cell. The figure shows also the different mechanism of action of 
EGFR–TKIs, which inhibit the binding with ATP in the intracellular space and consequent activation of the aforementioned cascade.
Abbreviations: ADCC, antibody-dependent cell cytolysis; AKT, protein kinase B; ATP, adenosine triphosphate; EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase kinase; mTORc, mammalian target of rapamycin complex; 































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





treatment for collection of pharmacokinetic data (already 
described in the “pharmacokinetics” paragraph), followed 
by subsequent administrations according to the treatment 
arm and cohort. Necitumumab was globally well tolerated 
in both arms, its most common toxicity being acneiform 
rash, generally mild (all grades: 55.2%; grade $3%: 3.3%), 
grade 1–2 diarrhea (41.4% in arm A and 19.4% in arm B; no 
grade $3 reported), and grade 1–2 nausea (10.3% in arm A 
and 22.6% in arm B; no grade $3 reported). Two patients 
from arm B enrolled in the 1,000 mg cohort experienced 
grade 3 headache associated with nausea, vomiting, and 
fever; this event was considered a dose-limiting toxicity 
and consequently the maximum tolerated dose was set at 
800 mg. Globally, 47 patients were evaluable for response: 
disease stabilizations in 16 (eight in each arm) and partial 
responses in two (one in each arm) were reported; 17 patients 
achieved a progression-free survival (PFS) of 3 months and 
nine reached a PFS of 6 months.13
Based on these findings, another Phase I trial was started 
in order to evaluate the pharmacologic characteristics of 
necitumumab in a population of Asian patients; in this study, 
15 Japanese patients received necitumumab in three differ-
ent cohorts: 600 mg on days 1 and 8 every 3 weeks, 800 mg 
on day 1 every 3 weeks, and 800 mg on days 1 and 8 every 
3 weeks (no escalation over 800 mg was planned, as this was 
the maximum tolerated dose in the previous trial). In this trial, 
no dose-limiting toxicity was reported at 600 or 800 mg, while 
the most frequent adverse events were headache (66.7%), dry 
skin (66.7%), pruritus (53.3%), and skin rash (53.3%), and 
most of them were mild or moderate (grade 1–2); a disease 
control rate (DCR) of 67% was reported.21
Phase ii trials
Phase II trials involving necitumumab in NSCLC are rela-
tively limited, and most available data have been collected 
from conference abstracts. In a single-arm Phase II trial, 
necitumumab (800 mg on days 1 and 8) was administered 
in combination with cisplatin (75 mg/m2 on day 1) and gem-
citabine (1,250 mg/m2 on days 1, 8) in a maximum of six 
3-week cycles as first-line treatment for 61 patients affected 
by advanced squamous NSCLC with the possibility to con-
tinue necitumumab as maintenance in case of responding or 
stable disease. Response rate (RR) and DCR were 48.1% and 
81.5%, while median PFS and OS were 5.6 and 11.7 months, 
respectively.22
In another Phase II trial, 167 patients with stage IV 
squamous NSCLC were randomized (2:1) to receive either 
carboplatin (area under the curve =6 on day 1), paclitaxel 
(200 mg/m2 on day 1), and necitumumab (800 mg on days 
1 and 8) or only carboplatin and paclitaxel every 21 days 
for a maximum of six cycles; the patients enrolled in the 
experimental arm could continue necitumumab as mono-
therapy in case of response or stabilization after completion 
of the combination treatment. Globally, RR was 48.9% in the 
experimental arm and 40.0% in the control arm, while DCR 
was 87.2% and 84.0%, respectively; the addition of necitu-
mumab, compared to chemotherapy alone, did not result in 
significant differences in terms of median OS (13.2 vs 11.2 
months; HR=0.83; P=0.379) or PFS (5.4 vs 5.6 months; 
HR=1.0; P not reported). Grade 3 hypomagnesemia and rash 
were more frequent in the experimental arm (5.7% vs 0% and 
2.8% vs 0%, respectively), while thromboembolic events of 
any grade were similar (3.8% vs 3.6%).23
Phase iii trials
The clinical efficacy of necitumumab combination with 
first-line chemotherapy for advanced NSCLC was evaluated 
in two large randomized, Phase III trials; one addressing 
patients with non-squamous histology (INSPIRE)24 and one 
addressing patients with squamous histology (SQUIRE).25 
The efficacy data of these trials have been summarized in 
Table 1. Both studies included a preplanned analysis of 
the EGFR expression, which was defined in the form of 
an immunohistochemistry (IHC) value called H-score,3 
which was also employed in the retrospective analysis of 
the FLEX trial with cetuximab5 and was computed on the 
basis of the percentage of cells expressing each IHC value 
(ranging from 0 to 3+) with the following formula: (1×% 
of cells expressing IHC 1+)+(2×% of cells expressing IHC 
2+)+(3×% of cells expressing IHC 3+), resulting in a value 
between 0 and 300. In the INSPIRE study (non-squamous 
carcinomas), the expression of EGFR was considered low if 
H-score was ,200, and high if H-score was $200; this cut-
off score was derived from the post hoc analysis of FLEX, 
where the addition of cetuximab to chemotherapy achieved 
a significant OS advantage in patients belonging to the high 
H-score population, while patients with low H-score had no 
advantage. The outcome data of the INSPIRE and SQUIRE 
trials based on H-score are reported in Table 2.
In the INSPIRE trial, patients with previously untreated, 
stage IV, non-squamous NSCLC were randomized (1:1) to 
receive 3-week cycles of treatment with cisplatin 75 mg/m2 plus 
pemetrexed 500 mg/m2 on day 1, either alone or in combination 
with necitumumab 800 mg on days 1 and 8 for a maximum of 
six cycles, with the option of receiving necitumumab mono-
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Necitumumab in non-small cell lung carcinoma
Table 1 Trial design and efficacy results of the INSPIRE and the SQUIRE trials
Trial INSPIRE24 SQUIRE25
Trial design Open-label, randomized Phase iii trial Open-label, randomized Phase iii trial
Addressed population Treatment-naïve, stage IV nonsquamous NSCLC Treatment-naïve, stage IV squamous NSCLC
Treatment arms Exp: Cisplatin (75 mg/m2 day 1) + pemetrexed 
(500 mg/m2 day 1) + necitumumab (800 mg days 1 and 8) 
every 3 weeks for six cycles followed by maintenance with 
necitumumab (800 mg/m2 days 1 and 8) every 3 weeks after 
the sixth cycle (until death, PD, or unacceptable toxicity)
Ctrl: Cisplatin (75 mg/m2 day 1) + pemetrexed 
(500 mg/m2 day 1) every 3 weeks for six cycles
Exp: Cisplatin (75 mg/m2 day 1) + gemcitabine 
(1,250 mg/m2 days 1 and 8) + necitumumab (800 mg 
days 1 and 8) every 3 weeks for six cycles followed 
by maintenance with necitumumab (800 mg/m2 days 1 
and 8) every 3 weeks after the sixth cycle (until death, 
PD, or unacceptable toxicity)
Ctrl: Cisplatin (75 mg/m2 day 1) + gemcitabine 
(1,250 mg/m2 days 1 and 8) every 3 weeks for six cycles
Randomization ratio 1:1 1:1
Number of evaluable 
patients 
633 (315 Exp and 318 Ctrl) 1,093 (545 Exp and 548 Ctrl)
endpoints Primary: OS
Secondary: DCR, ORR, PFS, PRO, TTF
Primary: OS
Secondary: DCR, ORR, PFS, PRO, TTF
Median OS (Exp vs Ctrl) 11.3 vs 11.5 months (HR=1.01; 95% Ci=0.84–1.21; P=0.96) 11.5 vs 9.9 months (HR=0.84; 95% Ci=0.74–0.96; P=0.01)
Median PFS (Exp vs Ctrl) 5.6 vs 5.6 months (HR=0.96; 95% Ci=0.80–1.16; P=0.66) 5.7 vs 5.5 months (HR=0.85; 95% Ci=0.74–0.98; P=0.02)
Median TTF (Exp vs Ctrl) 3.5 vs 4.3 months (HR=1.18; P=0.046) 4.3 vs 3.6 months (HR=0.84; P=0.006)
ORR (Exp vs Ctrl) 31% vs 32% (P=0.79) 31% vs 28% (P=0.40)
DCR (Exp vs Ctrl) 73% vs 74% (P not reported) 82% vs 77% (P=0.043)
ClinicalTrials.gov NCT00982111 NCT00981058
Abbreviations: 95% CI, 95% confidence interval; CTCAE, common terminology criteria for adverse events (version 3.0); Ctrl, control arm; DCR, disease control rate; 
exp, experimental arm; HR, hazard ratio; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free 
survival; PRO, patient reported outcome; TTF, time to treatment failure.
arm who remained stable or responding after the completion 
of combination treatment; the trial was designed as open label, 
because the known necitumumab-related skin toxicity would 
have prevented an effective blinding. After 15 months, an 
imbalance in deaths due to any cause and in grade 5 throm-
boembolic events was observed and hence the independent data 
monitoring committee recommended stopping enrollment and 
determined that, as a consequence of such events, the study 
was highly unlikely to achieve a survival benefit.26 At that time, 
633 patients had been randomized and data from 616 patients 
(304 in the experimental arm and 312 in the control arm) were 
available for the planned outcome analyses. The authors stated 
that severe (grade $3) adverse events were more frequent in 
the arm containing necitumumab than in the arm containing 
chemotherapy alone (51% vs 41%), including possibly specific 
treatment-related fatal adverse events (5% vs 3%).
In the experimental arm, the incidence of venous 
thromboembolism of any grade was 13% while that of 
grades 3, 4, and 5 were 6%, ,1%, and 1%, respectively; in 
the control arm, incidence of any grade was 8%, while that 
of grades 3, 4, and 5 were 2%, ,1%, and 1%, respectively. 
Skin toxicity was the most common adverse event observed 
with necitumumab (any grade: 78%, grade $3%: 16%) 
in comparison with the control arm (any grade: 19%, 
grade $3%: ,1%). The efficacy analysis showed that adding 
necitumumab to chemotherapy did not result in improvements 
in terms of PFS (5.6 vs 5.6 months; HR=0.96; 95% confi-
dence intervals (CI)=0.90–1.16; P=0.66) or OS (11.3 vs 11.5 
months; HR=1.01; 95% CI=0.84–1.21; P=0.96); additionally, 
overall RR was not different between the experimental and 
the control arm (31% vs 32%; odds ratio (OR)=0.96; 95% 
CI=0.68–1.34; P=0.79). Globally, 490 patients were evalu-
able for H-score, of which 290 (59%) were H-score low, 
while 200 (41%) were H-score high; H-score was unable to 
predict improved outcomes with the combination, including 
necitumumab: in the H-score low patients, the experimental 
and the standard arm were not different in terms of PFS (4.9 vs 
4.8 months; HR=0.95; 95% CI=0.73–1.23; P=0.68), OS 
(9.0 vs 9.7 months; HR=1.07; 95% CI=0.83–1.38; P=0.59), 
and RR (27% vs 26%; OR=1.06; 95% CI=0.63–1.78; 
P=0.84); similarly, among the H-score high patients, no 
difference was observed between the experimental and the 
standard arm in terms of PFS (5.6 vs 5.6 months; HR=0.94; 
95% CI=0.68–1.30; P=0.71), OS (15.0 vs 13.3 months; 
HR=1.03; 95% CI=0.75–1.43; P=0.85), and RR (40% vs 
39%; OR=1.01; 95% CI=0.57–1.78; P=0.98).24
In the other Phase III trial, SQUIRE, 1,093 patients 
with advanced SCC were randomized (1:1) to receive first-
line chemotherapy with cisplatin 75 mg/m2 on day 1 plus 
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every 21 days alone (548 patients) or in combination with 
necitumumab 800 mg on days 1 and 8 (545 patients); similar 
to INSPIRE, this trial was open label and, after six cycles 
of chemotherapy, patients in the experimental arm with 
controlled or responding disease were allowed to receive 
maintenance with necitumumab at the same dose. In this 
study, the safety assessment showed that skin toxicity was the 
most common adverse event associated with necitumumab 
(any grade: 79%, grade $3%: 8%), while it was less frequent 
in the control arm (any grade: 12%, grade $3%: ,1%); simi-
larly, the incidence of venous thromboembolic events was 
higher in the arm containing chemotherapy and necitumumab 
(any grade: 9%, grade $3%: 5%) than in the arm containing 
chemotherapy alone (any grade: 5%, grade $3%: 3%), 
although the rate of fatal thromboembolic events (including 
both arterial and venous events) was low and not different 
between the two arms. In the efficacy analysis, the experi-
mental arm achieved a significant advantage in terms of PFS 
(5.7 vs 5.5 months; HR=0.85; 95% CI=0.74–0.98; P=0.02) 
and OS (11.5 vs 9.9 months; HR=0.84; 95% CI=0.74–0.96; 
P=0.01); RR was not significantly different between the 
experimental and the control arm (31% vs 29%; P=0.40), 
while DCR favored the arm containing necitumumab 
(82% vs 77%; P=0.043). The analysis based on EGFR 
H-score (with the cut-off between low and high put at 200, 
as in INSPIRE) did not demonstrate a different benefit within 
Table 2 Outcome data for subpopulations based on EGFR H-score in the INSPIRE and SQUIRE trials
INSPIRE24
H-score high H-score low
CDDP-PEM-NEC CDDP-PEM CDDP-PEM-NEC CDDP-PEM
Patients, n 101 99 144 146
Overall survival
Median (months) 15.0 13.3 9.0 9.7




Median (months) 5.6 5.6 4.9 4.8




Response rate (%) 40 39 27 26




H-score high H-score low
CDDP-GEM-NEC CDDP-GEM CDDP-GEM-NEC CDDP-GEM
Patients, n 191 183 295 313
Overall survival
Median (months) 12.0 9.7 11.1 10.9




Median (months) 5.7 5.5 5.7 5.5




Response rate (%) 29 30 34 28
Odds ratio 0.97 1.27
P-value 0.88 0.17
interaction P-value 0.34
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Necitumumab in non-small cell lung carcinoma
H-score subpopulations (H-score high: 38%; H-score low: 
62%), as the survival advantage with necitumumab was 
confirmed in both subgroups and no significant difference 
was observed in each arm for H-score high vs H-score low, 
both in terms of PFS (experimental arm: 5.7 vs 5.7 months; 
HR=1.03; 95% CI=0.84–1.26; P=0.80; standard arm: 5.5 vs 
5.5 months; HR=0.96; 95% CI=0.78–1.19; P=0.74) and OS 
(experimental arm: 12.0 vs 11.1 months; HR=0.94; 95% 
CI=0.76–1.16; P=0.80; standard arm: 9.7 vs 10.9 months; 
HR=1.12; 95% CI=0.92–1.37; P=0.26). The authors 
reported that the HR for OS between the experimental and 
the standard arm in the EGFR H-score high population was 
0.75 (95% CI=0.60–0.94), while the HR in the H-score low 
population was 0.90 (95% CI=0.75–1.07); notably, the HR 
for PFS apparently followed a different trend, as it was 0.88 
(95% CI=0.70–1.11) in the H-score high and 0.83 (95% 
CI=0.69–0.99) in the H-score low populations. However, 
the interaction P-value was not significant for OS and PFS 
(0.24 and 0.68, respectively).25
The SQUIRE trial was subject to several further analyses, 
which added information about specific subgroups, quality of 
life, and potential predictive factors. In a subgroup analysis 
evaluating EGFR expressing patients (regardless of H-score) 
and patients with completely undetectable EGFR protein, 
most evaluable patients (95.2%) had some expression of 
EGFR and their characteristics were well balanced between 
the treatment arms, while only 4.8% were totally negative 
for EGFR; in the EGFR-positive population, the addition 
of necitumumab resulted in a significant improvement in 
terms of PFS (HR=0.84; 95% CI=0.72–0.97; P=0.018) 
and OS (HR=0.79; 95% CI=0.69–0.92; P=0.002) over the 
control arm, while in the subgroup of patients who were 
EGFR negative, no advantage in terms of PFS (HR=1.33; 
95% CI=0.65–2.70; P=0.428) or OS (HR=1.52; 95% 
CI=0.74–3.12; P=0.428) was observed with the addition of 
necitumumab to chemotherapy.27
Although SQUIRE was not designed to assess the safety 
and the effectiveness of continuing necitumumab after com-
pleting the combination, a post hoc analysis was conducted 
on those patients who were alive and progression-free after 
completion of chemotherapy; the HRs for OS and PFS in 
the post-induction period were 0.85 and 0.86, respectively, 
consistent with the overall SQUIRE data.28
Key subgroup analyses, including Eastern Cooperative 
Oncology Group performance status, sex, ethnicity, and age 
resulted in a generally consistent OS advantage in the experi-
mental arm; this advantage was not confirmed in patients 
aged $70 years (HR≈1.0), although the drug exposure for 
this subpopulation was reportedly reduced.29–31 Furthermore, 
the efficacy and the safety observed in a subpopulation of 
84 East Asian patients from the SQUIRE trial (43 enrolled 
in the experimental arm and 41 enrolled in the control arm) 
were reported as generally consistent with data from non-
East Asian patients.32
With regard to quality of life, an exploratory post hoc 
analysis of the lung cancer symptom scale did not show sig-
nificant differences in terms of time to symptom deterioration 
or in terms of required supportive care between the experi-
mental and the standard arm, while the baseline maximum 
severity score, defined as the worst (highest) score of any 
individual lung cancer symptom scale item at baseline, was 
suggested to have some prognostic and predictive value 
with the limitations of this analysis; notably, the addition of 
necitumumab resulted in better HR values in the subgroups 
with higher maximum severity score.33
Finally, a retrospective analysis evaluated the value of 
EGFR gene copy number assessed with fluorescence in situ 
hybridization (FISH), as a predictor of outcome in 557 evalu-
able patients; although a positive FISH does not qualify as 
a predictor of outcome with statistical significance, a trend 
toward significance was observed for both PFS (interaction 
P=0.057) and OS (interaction P=0.066), and the addition of 
necitumumab in the FISH-positive population resulted in an 
HR equal to 0.71 for PFS (95% CI=0.52–0.97) and 0.70 for 
OS (95% CI=0.52–0.96).34
Safety profile
The different trials involving necitumumab allowed the inves-
tigators to collect meaningful data about its safety profile and 
the drug-related adverse events. The main necitumumab-
related adverse events observed at the approved dose of 
800 mg in combination with chemotherapy were collected 
from INSPIRE and SQUIRE trials24,25 and are reported in 
Table 3. Notably, since the administration of necitumumab 
to nonprogressing patients was continued after completion 
of induction chemotherapy, the safety monitoring period was 
longer on the experimental arm, possibly introducing a bias 
favoring the control arm.
As previously reported, since EGFR is the main target 
of necitumumab, the most frequent toxicity involves skin 
reactions. This toxicity is explained by the presence of 
EGFR on a number of epidermal cells, including keratino-
cytes and sebocytes,35 and becomes manifest in the form 
of dry skin, acne, dermatitis, skin ulcer, or pruritus; most 
of these adverse events, however, were mild or moderate 
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profiles for other drugs belonging to the same class and 
should be managed in the same way.36 Notably, a correlation 
between occurrence of skin rash during the first two cycles 
and improved OS was suggested on the basis of an analysis 
of SQUIRE,37 which was consistent with similar observa-
tions reported with cetuximab.4 When taking into account 
blood examinations and laboratory values, the addition of 
necitumumab to chemotherapy did not result in an increased 
rate of anemia, leukopenia, or thrombocytopenia, while the 
most significant laboratory-related alteration was a reduc-
tion in magnesium levels; such toxicity is related to the 
presence of EGFR on cells forming distal and collecting 
tubules in the kidneys, which are normally involved in the 
regain of magnesium, and is further worsened by the renal 
toxicity associated with cisplatin (known as a magnesium-
depleting agent). Although the actual clinical relevance of 
this toxicity has yet to be defined properly,38 it is possible 
that electrolytes disorders might partially be correlated with 
cardiac dysfunctions; furthermore, a cardiac arrest/sudden 
death ratio of 3% (compared to 0.6% in the control arm) 
was reported in SQUIRE, although most of these patients 
were affected by cardiologic comorbidities; however, it 
should be taken into account that cisplatin-based regimens 
are commonly associated with hypomagnesemia.26,39 Some 
adverse events at least partially correlated with the addition 
of necitumumab to chemotherapy were observed with a 
different frequency according to the employed regimen and 
were generally more relevant to the cisplatin–pemetrexed 
combination. The most concerning toxicity was represented 
by venous thromboembolic events, a significant proportion of 
which were severe (5%–8%), while the incidence of arterial 
thromboembolic events did not seem to be increased by the 
use of necitumumab or other EGFR mABs. While it should 
be noted that venous thromboembolism is common in lung 
cancer patients, and especially in those patients receiving 
chemotherapy, this toxicity apparently characterizes the 
whole drug class (while it is not shared with EGFR tyrosine 
kinase inhibitors); however, its physiopathological mecha-
nisms are still unclear, although they might be correlated 
to an indirect disruption of the vascular endothelial growth 
factor signaling.40 Fatigue was another commonly observed 
adverse event, and, although it is a typical side effect of 
combination chemotherapy, the authors of the INSPIRE 
trial reported that its frequency was increased in the combi-
nation of cisplatin–pemetrexed–necitumumab compared to 
cisplatin–pemetrexed, while no significant difference was 
reported in SQUIRE. Another category of adverse events 
at least partially associated with the association of necitu-
mumab and chemotherapy with cisplatin–pemetrexed was 
represented by eye disorders, which included events such as 
dryness or conjunctivitis. Finally, the allergy-related adverse 
events were not significantly higher in the experimental arms 
of INSPIRE and SQUIRE; this difference between necitu-
mumab and cetuximab, which is characterized by a high 
prevalence of hypersensitivity reactions, might be explained 
by the fully human structure of the former and the chimeric 
structure of the latter.41
Regulatory affairs
Based on the data from SQUIRE, in November 2015, 
necitumumab was approved by the US Food and Drug 
Administration for the first-line treatment of advanced SCC 
in combination with cisplatin and gemcitabine.42 In December 
2015, a positive opinion from the Committee for Medicinal 
Table 3 Relevant drug-related toxicities from trials involving necitumumab in combination with platinum-based chemotherapy in 
advanced NSCLC, based on published data from iNSPiRe24 and SQUIRE25
Adverse event Necitumumab plus cisplatin 
and pemetrexed
Necitumumab plus cisplatin 
and gemcitabine
% any grade % grade $3 % any grade % grade $3
Skin disorders 78 15 79 8
Rash 41 8 44 4
Dermatitis acneiform 14 3 15 1
Acne 4 ,1 9 ,1
Pruritus 10 ,1 7 ,1
Skin ulcer ,1 ,1 ,1 ,1
Fatigue 56 11 42 7
Hypomagnesemia 27 8 31 9
eye disorders 16 0 7 ,1
venous thromboembolic events 13 8 9 5
Cardio-respiratory arrest/sudden death 0 ,1 0 3
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Necitumumab in non-small cell lung carcinoma
Products for Human Use of the European Medicines Agency 
(EMA) ultimately resulted in the authorization for the use 
of necitumumab in combination with cisplatin and gemcit-
abine as the first-line treatment for adult patients affected 
by EGFR-expressing advanced squamous NSCLC in 
February 2016.43,44 While testing for EGFR protein expres-
sion is not necessary in order to prescribe necitumumab 
according to US Food and Drug Administration, the specific 
request from EMA is connected to the subgroup analysis 
reporting that, as previously described, a positive EGFR 
protein expression was identified in specimens from nearly 
all the patients evaluable for IHC in the SQUIRE trial and 
that the smaller proportion of patients with undetectable 
EGFR expression did not achieve improved outcomes with 
the addition of necitumumab.
Discussion
The most relevant advances in the treatment of advanced 
NSCLC over the past decade involved almost exclusively 
non-squamous histology, mostly thanks to the exploitation of 
oncogenic drivers. Necitumumab represents quite a unique 
model in the lung cancer landscape, as its addition to standard 
chemotherapy resulted in a significant survival advantage for 
patients with SCC, making it the first targeted agent to be 
approved in combination with first-line chemotherapy for 
squamous histology. In the Phase III trials involving the addi-
tion of necitumumab to chemotherapy, the benefit observed 
in SCC (as well as its lack of in non-squamous histology) 
was generally consistent among subpopulations selected on 
the basis of clinical features and EGFR expression measured 
as H-score, although no survival benefit was demonstrated 
in a limited population of patients with SCC lacking EGFR 
expression. Notably, the lack of benefit in this population 
induced EMA to limit the availability of necitumumab to 
EGFR-positive patients in Europe, although this decision 
was based on a relatively small subpopulation (4.8%) com-
pared to the global SQUIRE population; further trials and 
analyses might eventually add valuable information to this 
specific setting.
One possible limitation to the use of necitumumab lies 
in the current lack of prospective data on reliable predictive 
biomarkers that are able to improve patient selection; in 
fact, the addition of necitumumab to standard chemotherapy 
is associated with increased toxicity, albeit in line with the 
drug class. Additionally, as the cost–benefit value of new 
antineoplastic agents is a major cause of concern at the cur-
rent time,45 being able to select the patients who are going 
to benefit the most from the addition of necitumumab might 
actually improve its cost–benefit ratio and ultimately increase 
its value. Notably, while a retrospective analysis of SQUIRE 
reported improved HR for OS and PFS in patients with 
increased EGFR gene copy number determined by FISH, the 
retrospective nature of this evaluation does not allow to draw 
definitive conclusions, but at the same time might generate 
additional working hypotheses, which might be the basis of 
prospective studies designed to explore the role of FISH in 
necitumumab-based regimens.
Finally, further studies involving necitumumab are being 
planned or are currently ongoing; one of these studies is 
of particular relevance, as it aims to explore the possible 
role of the drug in association with osimertinib (a recently 
approved EGFR inhibitor specifically designed to address 
the T790M mutation), actually acting as a dual blockade on 
the receptor;46 despite being a Phase I trial, this study might 
open some additional perspectives for further development 
of this agent. Other trials are currently exploring the effect 
of combining necitumumab with other systemic treatments, 
such as alternative chemotherapy regimens,47 investigational 
targeted therapies,48,49 or immune check-point inhibitors.50
In summary, necitumumab is an interesting addition 
to the therapeutic options available to medical oncologists 
and patients with advanced SCC and might have a role in 
filling the current therapeutic gap between squamous and 
nonsquamous lung cancer; additionally, further studies 
addressing selected patient populations might potentially 
extend the role of this drug in the treatment of advanced 
NSCLC, improve its risk–benefit ratio, and increase its 
cost-effectiveness.
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